Recent Updates
Recently added Catalysts
SBC Positive Sentiment Score: 65/100

SBC Medical Group Holdings Announces First Quarter 2025 Financial Results Irvine, Calif.

Key Takeaway: SBC Medical Group Holdings has reported its financial results for the first quarter of 2025, highlighting a 14% year-over-year revenue decrease primarily due to discontinuations of certain business segments. However, the company saw a significant improvement in its operating margin, rising from 45% to 51%, and net income increased by 15% compared to the previous year. SBC is positioning itself for strategic expansion while experiencing rising global demand for aesthetic medical services. The company is optimistic about its transition and long-term growth prospects despite facing some operational challenges.

Market Sentiment Analysis

POSITIVE FACTORS

  • Operating margin improved from 45% to 51% year-over-year.
  • Net income attributable to SBC Medical Group increased by 15% year-over-year.
  • Global demand for aesthetic medical services is rising.
  • SBC is preparing for strategic expansion and optimizing its profitability.

CONCERNS & RISKS

  • Revenue decreased by 14% year-over-year due to the discontinuation of the staffing business.
  • Disposals of subsidiaries like Sky Net Academy and SBC Kijimadaira Resort impacted revenue.
  • Termination of the staffing services business is a setback.

Full Press Release Details

Medical Group Holdings Announces First Quarter 2025 Financial Results
Calif., May 15, 2025 (Business Wire) -
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"), a global owner, operator
and provider of management services and products to cosmetic treatment centers, today announced its financial results for the three months
ended March 31, 2025.
Quarter 2025 Highlights
Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, "SBC is actively preparing for strategic expansion by enhancing
its platform, optimizing its profitability structure, and stabilizing its business through revised pricing strategies and adapting to
changing market dynamics. In the first quarter of 2025, we were pleased to see the expansion of Medical Corporations (MCs) gaining traction
in our franchising, procurement and rental business segments as global demand for aesthetic medical services continued to rise; meanwhile,
revenue decrease in the quarter primarily reflected the discontinuation of our staffing business and divestures of Sky Net Academy ("SNA")
and SBC Kijimadaira Resort ("Kijimadaira"). In the midst of this transition, operating margin improved from 45% in
the first quarter 2024, to 51% in the first quarter 2025. Additionally, net income attributable to SBC Medical Group increased 15% year-over
year, further demonstrating the strength of our business model transition and execution. As we move ahead, we remain confident in our
ability to build a scalable franchise model while accelerating expansion across domestic and international markets, driving long-term
value for shareholders and positioning the Company to capitalize on future opportunities."
and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measure, please see the section of "Use
of Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results."
The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, but does not take account
customers of AHH Clinics
The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, but does not take account
customers of AHH Clinics, but excluding free counseling
Quarter 2025 Financial Results
revenues were $47 million, a decrease of 14% year-over-year reflecting the negative impact of the discontinuation of the staffing business
and the disposal of subsidiaries partially offset by increased demand for medical materials and equipment from the expansion of Medical
income for the three months ended March 31, 2025 was $22 million, compared to $19 million in the same period of 2024. The increase was
largely attributed to the impact of a special gain associated with the maturity of a life insurance policy.
was $25 million, a decrease of 3% year-over-year primarily driven by lower in revenue following the termination
of the staffing services business and the deconsolidation of SNA and Kijimadaira.
Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment
centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited
to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and
training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals,
construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic
products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies,
trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise
clinic's customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.
more information, visit https://sbc-holdings.com/
of Non-GAAP Financial Measures
Company uses non-GAAP measures, such as EBITDA, in evaluating its operating results and for financial and operational decision-making
purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes
that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall
understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics
used by the Company's management in its financial and operational decision-making.
non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial
measures have limitations as analytical tools, and when assessing the Company's operating performance, cash flows or liquidity,
investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other
consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.
Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures,
all of which should be considered when evaluating the Company's performance.
more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP
press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions,
but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently
uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with
respect to, among other things, the Company's financial performance; growth in revenue and earnings; business prospects and opportunities;
and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates," "believes,"
"plans," "projected," "predicts," "potential," or "hopes" or the negative
of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current
only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are
difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees
of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement
is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge
from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in
global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk
Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"),
which are accessible on the SEC's website at www.sec.gov.
SBC MEDICAL GROUP HOLDINGS INCORPORATED
CONSOLIDATED BALANCE SHEETS
March 31, 2025 December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents $ 132,055,823 $ 125,044,092
Accounts receivable 1,633,456 1,413,433
Accounts receivable - related parties 30,557,912 28,846,680
Accounts receivable 30,557,912 28,846,680
Inventories 1,694,765 1,494,891
Finance lease receivables, current - related parties 7,281,088 5,992,585
Customer loans receivable, current 8,903,724 10,382,537
Prepaid expenses and other current assets 32,970,169 11,276,802
Total current assets 215,096,937 184,451,020
Non-current assets:
Property and equipment, net 8,523,351 8,771,902
Intangible assets, net 1,543,779 1,590,052
Long-term investments, net 3,703,699 3,049,972
Goodwill, net 4,780,616 4,613,784
Finance lease receivables, non-current - related parties 10,648,402 8,397,582
Operating lease right-of-use assets 5,152,104 5,267,056
Finance lease right-of-use assets 522,055 -
Deferred tax assets 2,513,653 9,798,071
Customer loans receivable, non-current 4,525,883 5,023,551
Long-term prepayments 1,922,709 1,745,801
Long-term investments in MCs - related parties 18,691,785 17,820,910
Long-term investments 18,691,785 17,820,910
Other assets 6,980,816 15,553,453
Total non-current assets 69,508,852 81,632,134
Total assets $ 284,605,789 $ 266,083,154
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 17,854,422 $ 13,875,179
Accounts payable - related parties 1,141,762 659,044
Accounts payable 1,141,762 659,044
Current portion of long-term loans 66,950 96,824
Notes and other payables, current - related parties 1,422,976 26,255
Advances from customers 525,497 820,898
Advances from customers - related parties 10,155,134 11,739,533
Advances from customers 10,155,134 11,739,533
Income tax payable 1,624,002 18,705,851
Operating lease liabilities, current 4,131,154 4,341,522
Finance lease liabilities, current 157,532 -
Accrued liabilities and other current liabilities 8,564,250 8,103,194
Due to related party 2,822,537 2,823,590
Total current liabilities 48,466,216 61,191,890
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE
SHEETS - (Continued)
March 31, 2025 December 31, 2024
Non-current liabilities:
Long-term loans 6,798,045 6,502,682
Notes and other payables, non-current - related parties 12,413 5,334
Deferred tax liabilities 346,432 926,023
Operating lease liabilities, non-current 1,312,819 1,241,526
Finance lease liabilities, non-current 195,572 -
Other liabilities 1,151,857 1,193,541
Total non-current liabilities 9,817,138 9,869,106
Total liabilities 58,283,354 71,060,996
Stockholders' equity:
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024) - -
Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 103,611,251 and 102,750,816 shares outstanding as of March 31, 2025 and December 31, 2024, respectively) 10,388 10,302
Additional paid-in capital 62,513,837 62,513,923
Treasury stock (at cost, 270,000 shares as of March 31, 2025 and December 31, 2024) (2,700,000 ) (2,700,000 )
Retained earnings 210,965,453 189,463,007
Accumulated other comprehensive loss (44,343,412 ) (54,178,075 )
Total SBC Medical Group Holdings Incorporated stockholders' equity 226,446,266 195,109,157
Non-controlling interests (123,831 ) (86,999 )
Total stockholders' equity 226,322,43 5 195,022,158
Total liabilities and stockholders' equity $ 284,605,789 $ 266,083,154
The accompanying notes are an integral part of these
unaudited consolidated financial statements.
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
COMPREHENSIVE INCOME
For the Three Months Ended March 31,
2025 2024
Revenues, net - related parties $ 45,257,145 $ 50,470,207
Revenues, net 2,071,556 4,337,835
Total revenues, net 47,328,701 54,808,042
Cost of revenues (including cost of revenues from related parties of $3,456,928 and $1,797,359 for the three months ended March 31, 2025 and 2024, respectively) 9,595,617 15,288,667
Gross profit 37,733,084 39,519,375
Operating expenses:
Selling, general and administrative expenses 13,531,010 15,058,490
Total operating expenses 13,531,010 15,058,490
Income from operations 24,202,074 24,460,885
Other income (expenses):
Interest income 55,333 17,689
Interest expense (6,207 ) (3,008 )
Other income 151,328 349,681
Other expenses (1,697,259 ) (1,436,656 )
Gain on redemption of life insurance policies 8,746,138 -
Gain on disposal of subsidiary - 3,813,609
Total other income 7,249,333 2,741,315
Income before income taxes 31,451,407 27,202,200
Income tax expense 9,959,457 8,451,984
Net income 21,491,950 18,750,216
Less: net loss attributable to non-controlling interests (10,496 ) (7,536 )
Net income attributable to SBC Medical Group Holdings Incorporated $ 21,502,446 $ 18,757,752
Other comprehensive income (loss):
Foreign currency translation adjustment $ 9,808,327 $ (10,193,852 )
Total comprehensive income 31,300,27 7 8,556,364
Less: comprehensive loss attributable to non-controlling interests (36,832 ) (92,000 )
Comprehensive income attributable to SBC Medical Group Holdings Incorporated $ 31,337,10 9 $ 8,648,364
Net income per share attributable to SBC Medical Group Holdings Incorporated*
Basic and diluted $ 0.21 $ 0.20
Weighted average shares outstanding*
Basic and diluted 103,276,637 94,192,433
The accompanying notes are an integral part of these
unaudited consolidated financial statements.
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Three Months Ended March 31,
2025 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 21,491,950 $ 18,750,216
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense 628,304 1,018,477
Non-cash lease expense 985,184 1,052,123
Provision for credit losses 25,102 152,579
Fair value change of long-term investments 140,581 938,511
Gain on disposal of subsidiary - (3,813,609 )
Gain on redemption of life insurance policies (8,746,138 ) -
Gain on disposal of property and equipment (12,375 ) -
Deferred income taxes 7,016,227 (360,582 )
Changes in operating assets and liabilities:
Accounts receivable (147,925 ) (383,254 )
Accounts receivable - related parties (295,505 ) 4,775,935
Inventories (124,279 ) (34,802 )
Finance lease receivables - related parties (2,779,253 ) (814,608 )
Customer loans receivable 4,501,760 2,858,633
Prepaid expenses and other current assets (3,150,243 ) 610,059
Long-term prepayments 98,164 138,212
Other assets 318,351 (328,818 )
Accounts payable 3,235,017 (8,937,435 )
Accounts payable - related parties 441,481 -
Notes and other payables - related parties (548,077 ) (1,104,968 )
Advances from customers (328,791 ) (1,451,008 )
Advances from customers - related parties (2,114,829 ) (161,936 )
Advances from customers (2,114,829 ) (161,936 )
Income tax payable (17,635,239 ) (6,552,783 )
Operating lease liabilities (1,036,605 ) (1,067,196 )
Accrued liabilities and other current liabilities 63,764 (1,604,603 )
Other liabilities (98,005 ) 3,032
NET CASH PROVIDED BY OPERATING ACTIVITIES 1,928,621 3,682,175
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment (253,725 ) (702,281 )
Purchase of convertible note - (1,700,000 )
Prepayments for property and equipment (501,253 ) -
Advances to related parties - (367,579 )
Purchase of long-term investments (635,145 ) -
Long-term loans to others (12,783 ) (44,865 )
Repayments from related parties 70,000 215,000
Repayments from others 30,680 21,422
Disposal of subsidiary, net of cash disposed of - (815,819 )
Proceeds from disposal of property and equipment 323,419 -
NET CASH USED IN INVESTING ACTIVITIES (978,807 ) (3,394,122 )
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Three Months Ended March 31,
2025 2024
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings from related parties 15,000 -
Repayments of long-term loans (55,873 ) (30,354 )
Repayments of finance lease liabilities (223,454 ) -
Repayments to related parties (16,053 ) (9,873 )
NET CASH USED IN FINANCING ACTIVITIES (280,380 ) (40,227 )
Effect of exchange rate changes 6,342,297 (7,089,208 )
NET CHANGE IN CASH AND CASH EQUIVALENTS 7,011,731 (6,841,382 )
CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD 125,044,092 103,022,932
CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD $ 132,055,823 $ 96,181,550
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense $ 6,207 $ 3,008
Cash paid for income taxes $ 20,577,290 $ 16,172,526
NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment transferred from long-term prepayments $ 125,287 $ -
Operating lease right-of-use assets obtained in exchange for operating lease liabilities $ 102,599 $ -
Finance lease right-of-use assets obtained in exchange for finance lease liabilities $ 581,129 $ -
Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications $ 358,358 $ 1,078,611
Payables to related parties in connection with loan services provided $ 1,922,224 $ 10,951,451
Issuance of common stock as incentive shares $ 86 $ -
R edemption proceeds receivable on life insurance policies $ 17,735,717 $ -
The accompanying notes are an integral part of these
unaudited consolidated financial statements.
OF GAAP TO NON-GAAP FINANCIAL MEASURES
MEDICAL GROUP HOLDINGS INCORPORATED
Reconciliations of GAAP and Non-GAAP Results
For the Three Months Ended March 31,
2025 2024
Total revenues, net $ 47,328,701 $ 54,808,042
Income from operations 24,202,074 24,460,885
Depreciation and amortization expense 628,304 1,018,477
EBITDA 24,830,378 25,479,362
EBITDA margin 52 % 46 %
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
Bill Zima / Managing Partner

Frequently Asked Questions

What were SBC Medical's Q1 2025 revenues?

SBC Medical's Q1 2025 revenues were $47 million, a 14% decrease year-over-year.

How did SBC Medical's net income change in Q1 2025?

Net income for Q1 2025 increased 15% year-over-year, reaching $22 million.

What impact did staffing business discontinuation have?

The discontinuation of the staffing business caused a decrease in quarterly revenue.

How did SBC Medical optimize its profitability?

SBC Medical optimized profitability by revising pricing strategies and enhancing its platform.

What is the operating margin for Q1 2025?

The operating margin improved to 51% in Q1 2025, up from 45% the previous year.

Last updated: May 15, 2025